Patents by Inventor Keith BOUCHARD

Keith BOUCHARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20260007725
    Abstract: Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).
    Type: Application
    Filed: September 11, 2025
    Publication date: January 8, 2026
    Inventors: Walter C. VOEGTLI, Michael Baranello, Keith Bouchard
  • Alkaline phosphatase polypeptides and methods of use thereof
    Patent number: 12433938
    Abstract: Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: October 7, 2025
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Walter C. Voegtli, Michael Baranello, Keith Bouchard
  • Anti-ALK2 antibodies and uses thereof
    Patent number: 12428484
    Abstract: Provided herein are antibodies that bind to activin receptor-like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth. Also provided are polynucleotides encoding the antibodies, vectors comprising the polynucleotides, and cells that produce the antibodies.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: September 30, 2025
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Jeffrey William Hunter, Julian Chandler, Keith Bouchard, Andre Marozsan, Patricia Bento, Anjli Kukreja
  • KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME
    Publication number: 20240262877
    Abstract: Described herein are fusion proteins which include factor H catalytic domains and may include VHH domains, factor H-related protein 5 domains, or integrin binding domains, and the use of such fusion proteins in methods of treatment of diseases mediated by complement alternative pathway activation or dysregulation, for example, kidney diseases.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 8, 2024
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Keith Bouchard, Jeffrey William Hunter, Bruce A. Andrien, Jr., Sung-Kwon Kim, Julian Chandler
  • ANTI-ALK2 ANTIBODIES AND USES THEREOF
    Publication number: 20220098310
    Abstract: Provided herein are antibodies that bind to activin receptor—like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth. Also provided are polynucleotides encoding the antibodies, vectors comprising the polynucleotides, and cells that produce the antibodies.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 31, 2022
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Jeffrey William Hunter, Julian Chandler, Keith Bouchard, Andre Marozsan, Patricia Bento, Anjli Kukreja
  • FUSION PROTEINS AND METHODS OF TREATING COMPLEMENT DYSREGULATION USING THE SAME
    Publication number: 20220009979
    Abstract: Described herein are fusion proteins that include two fragments of factor H, a fragment of factor H and an Fc domain, or a fragment of factor H, a fragment of CR2, and an Fc domain. The use of such proteins in methods of treatment for diseases mediated by alternative complement pathway dysmegulation.
    Type: Application
    Filed: August 22, 2019
    Publication date: January 13, 2022
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Julian Chandler, Christian Cobaugh, Keith Bouchard, Jeffrey Hunter
  • ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210169994
    Abstract: Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).
    Type: Application
    Filed: December 9, 2020
    Publication date: June 10, 2021
    Inventors: Walter C. VOEGTLI, Michael BARANELLO, Keith BOUCHARD